NEOG Neogen Corporation
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis. The company has a strategic collaboration with Hinalea Imaging Corp. to develop digital imaging solutions for food safety and quality inspection. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.…
Industry Peers
Medical DevicesKey Statistics
About Neogen (NASDAQ: NEOG)
›
Neogen (NASDAQ: NEOG) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 2,636 employees.
The shares were at 10.85 USD on 19 November 2026, up 69.5% over 52 weeks. Its 52-week range is 5.370 USD to 14.18 USD: the price is 23.5% below the high and 102.0% above the low.
Its market capitalisation is 2.37B USD.
Neogen reports return on equity of -0.4%, an operating margin of -0.8% and revenue up 6.5% year over year.
Its debt exceeds its cash by 602.30M USD, a debt-to-equity ratio of 0.38. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 3 analysts cover the stock, with an average rating of Buy; their mean price target of 14.00 USD is 29.0% above the current price. The next earnings report is expected on 7 January 2027.